Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Update

Bioxytran, Inc. (OTCMKTS:BIXT) saw a significant increase in short interest in March. As of March 31st, there was short interest totalling 83,800 shares, an increase of 70.3% from the March 15th total of 49,200 shares. Based on an average daily trading volume, of 872,700 shares, the short-interest ratio is currently 0.1 days. Currently, 0.3% of the shares of the stock are short sold.

Bioxytran Stock Up 4.2 %

OTCMKTS:BIXT opened at $0.18 on Friday. The firm has a market capitalization of $15.95 million, a PE ratio of -17.94 and a beta of 0.98. The stock’s 50-day simple moving average is $0.13 and its 200 day simple moving average is $0.11. Bioxytran has a twelve month low of $0.06 and a twelve month high of $0.23.

Bioxytran (OTCMKTS:BIXT) last announced its earnings results on Thursday, April 3rd. The company reported ($0.01) EPS for the quarter.

Bioxytran Company Profile

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.